In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on BioCryst (BCRX – Research Report), with a price target of $20.00.
Stacy Ku has given his Buy rating due to a combination of factors that highlight BioCryst’s promising financial outlook and market position. The company reported impressive sales figures for Orladeyo, surpassing previous guidance and demonstrating strong patient demand and retention. This success has led to an increased sales forecast for 2025, reflecting confidence in continued growth and patient transition to paid drug.
Moreover, Stacy Ku emphasizes the valuation disconnect for Orladeyo, which is trading at a discount relative to its potential. Despite concerns about the competitive landscape, expert opinions suggest that Orladeyo will maintain its dominance in the oral segment for HAE prophylaxis. The company’s strategic guidance and financial stability, with expectations of reaching positive cash flow by the second half of 2025, further support the Buy rating. Additionally, the long-term retention rate and the potential for Orladeyo to become a billion-dollar product reinforce the positive outlook.
In another report released on February 18, JMP Securities also reiterated a Buy rating on the stock with a $18.00 price target.